NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology
Video Journal of Hematology & Hematological Oncology (VJHemOnc)’s Post
More Relevant Posts
-
NEW #MPN Session from #ASH23🩸 💬 This EXCLUSIVE discussion features leading experts Ruben Mesa, MD, Claire Harrison & Jean-Jacques Kiladjian, who discuss key updates in the #treatment and #management of #myeloproliferativeneoplasms (#MPNs) following the 65th ASH Annual Meeting and Exposition The experts cover a variety of topics, including #novelagents being explored in essential #thrombocythemia (ET), updates in the treatment of #polycythemiavera (PV), and novel combinations being evaluated in #myelofibrosis (MF) 🔦 Take a look 👉 https://lnkd.in/eXeXjSFj #HemOnc #MPNsm American Society of Hematology
To view or add a comment, sign in
-
Last week I presented the first results of the phase 2 ICON study at the European Hematology Association (EHA) conference in Madrid. In the ICON study, relapsed/refractory multiple myeloma patients were treated with iberdomide, low-dose cyclophosphamide and dexamethasone. Iberdomide is a novel cereblon E3 ligase modulator (CELMoD™) with improved direct anti-myeloma activity and immune-stimulatory effects. This treatment regimen resulted in a ORR of 82% and a median PFS of 17.8 months in patients with 2-4 prior lines of therapy. This fully oral, well tolerated, and active combination warrants further evaluation in RRMM. The full abstract is available online: https://lnkd.in/eUqb4Vaq What an interesting conference the #EHA2024 has been! Thanks to all co-authors and my supervisors Niels Van De Donk, Sonja Zweegman and Tuna Mutis.
To view or add a comment, sign in
-
📢All 12 manuscripts in the #SpecialIssue “#Hematologic #Malignancies: Challenges from Diagnosis to Treatment”, led by Dr. Ioanna Sakellari and Dr. Eleni Gavriilaki, Hematology Department and Dr. Eleni Gavriilaki, have been published! 🎉🎉 📌You are welcome to read via the following link: https://lnkd.in/dyADYnGy
To view or add a comment, sign in
-
New publication 📝 Retrospective analysis published in Hematology provides new insights for #AcuteLymphoblasticLeukemia, see: https://loom.ly/vnLhcDM #ALLsm #leusm #MedEducation
To view or add a comment, sign in
-
NEW from #ASH2023 | CD33-TIM3 dual #CARTcells enhance specificity of #AML treatment 🎥 🩸 Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, discusses the three main approaches and concepts within CAR T-cell therapy, highlighting her work on #CD33 and #TIM3 dual-targeting #CARTcells These cells are engineered to target only those cells expressing both the #CD33 and TIM3 #antigens, leading to an increase in specificty when treating #acutemyeloidleukemia (#AML) and allowing for the treatment of patients without the need for #allogeneic #stemcell #transplantation 💡 Give it a watch to learn more 👉 https://lnkd.in/eBWDW_ep #HemOnc American Society of Hematology #Leusm
To view or add a comment, sign in
-
How can your laboratory help reduce unnecessary complications for newly diagnosed Multiple Myeloma patients? Find out how from Prof. Guy Pratt who discusses how your laboratory can help guide blood test requesting and appropriate hematology referral. Download our case studies from hospitals in the United Kingdom, United States and Spain by here: https://hubs.li/Q02phTNn0
To view or add a comment, sign in
-
Today we are working at conference EHA-KCS Hematology Tutorial on Recent Advances in Lymphoid and Myeloid Malignancies
To view or add a comment, sign in
-
We are excited to provide updated clinical safety and efficacy data from 7 transfusion-dependent beta thalassemia patients treated with renizgamglogene autogedtemcel (reni-cel) in the Phase 1/2 EdiThal clinical trial at European Hematology Association (EHA) annual congress. Treated patients had early and robust increases of total hemoglobin (Hb) and fetal hemoglobin, with total Hb rising to or above the transfusion independence threshold of 9.0 g/dL. All patients have been transfusion free for a range of 4.1 to 12.8 months after receiving the last red blood cell transfusion at 0.5–2.2 months post-reni-cel infusion. Reni-cel was well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. #BetaThalassemia #Biotechnology #Cas12a #CellTherapy #ClinicalTrials #CRISPR #EHA #GeneEditing #Hematology
#BREAKING: Editas Medicine announces new safety and efficacy data from the EdiTHAL trial of reni-cel in 7 patients with transfusion-dependent beta thalassemia, presented at the European Hematology Association Annual Congress. Read the press release for details: https://bit.ly/4ckMb7T #EHA2024 #geneediting #thalassemia
To view or add a comment, sign in
-
Unlock the secrets of hematology staining techniques with our latest blog post on the Wright-Giemsa stain! Perfect for laboratory professionals and students, this guide provides step-by-step instructions to help you achieve precise and accurate results 🔬🎨 Dive into the details here: https://bit.ly/3ycvOvL #WrightGiemsa #LabTutorial #HardyDiagnostics
How to do a Wright-Giemsa Stain
hardydiagnostics.com
To view or add a comment, sign in
-
#Congress | 🔎 What subjects were amplified by #HCPs through social media during #EHA2024? In June, took place the European Hematology Association (EHA) 2024 Hybrid Congress. The following pages provide a brief overview of the volume of conversations, the share of voice of clinical trials most discussed, or top hashtags. Moreover, discover a focus on #multiplemyeloma with the topics of discussions. Access the SML EHA2024 full report by clicking this link 👉 https://lnkd.in/e6-MYzHj
To view or add a comment, sign in
1,773 followers